Kimberly-Clark, producer of shopper items and private care merchandise, is finest identified for its paper-based merchandise, together with Scott, Cottonelle, Kleenex, Kotex, Huggies, and Pull-ups.
The corporate is now increasing its portfolio with extra on a regular basis American merchandise by a strategic acquisition.
On November 3, Kimberly-Clark introduced the acquisition of Kenvue, the maker of Tylenol, Neutrogena, Aveeno, and different manufacturers, in a deal valued at roughly $48.7 billion.
“Over the last several years, Kimberly-Clark has undertaken a significant transformation to pivot our portfolio to higher-growth, higher-margin businesses while rewiring our organization to work smarter and faster,” defined Kimberly-Clark CEO Mike Hsu.
A purported hyperlink between Tylenol and autism led to the decline of Tylenol maker Kenvue’s inventory by 21.7% 12 months thus far.
Picture supply: Chung/Politico/Bloomberg by way of Getty Pictures
Kimberly-Clark’s acquisition boosts Kenvue inventory
The mixed firm, Kimberly-Clark and Kenvue, is predicted to generate roughly $32 billion in annual internet income in 2025 and $7 billion in adjusted EBITDA.
The deal is among the many most vital company takeovers of the 12 months and is already benefiting the inventory value of controversial Tylenol maker Kenvue.
The corporate’s inventory, which was up 17% in pre-market buying and selling, is now buying and selling 15.8% larger, coinciding with its Q3 2025 earnings report, which reported a 3.5% decline in internet gross sales.
In the meantime, the inventory of Kimberly-Clark is buying and selling 12.9% decrease, a brand new 52-week low for the worldwide shopper items big.
Associated: Tylenol belief disaster: Trump, RFK Jr. and Texas lawsuits slam Kenvue
Based on the official announcement, the acquisition goals to leverage the mixed firm’s scale, model fairness, and distribution energy throughout greater than 175 nations.
On the closing of the deal, anticipated within the second half of 2026, topic to regulatory approval, Kenvue shareholders are anticipated to personal 46% and Kimberly-Clark 54% of the mixed shares.
Extra Well being Care:
- How AI May Monitor Mind Well being and Discover Dementia Soone
- Well being insurers make a serious transfer older Individuals received’t like
- How the federal government shutdown impacts Social Safety, Medicare
The announcement follows a collection of management adjustments at Kenvue, together with the appointment of Kirk Perry as everlasting CEO and Jonathan Halvorson as chief digital and advertising officer, efficient November 17.
Halvorson is acknowledged for main AI-driven advertising and digital commerce initiatives, expertise which can be prone to play a pivotal function in aligning the now-merged firm’s world digital technique.
Perry believes that the acquisition will convey larger worth to the shareholders whereas growing potential development alternatives.
The Tylenol autism controversy
The information comes as Kenvue maker Tylenol has been embroiled in litigation surrounding the alleged relationship between Tylenol and autism in youngsters.
In October, the Texas Lawyer Common’s Workplace filed a lawsuit towards Kenvue and Johnson & Johnson, alleging misleading advertising of Tylenol to pregnant girls.
This got here weeks after U.S. Well being and Human Providers Secretary Robert F. Kennedy Jr. asserted a hyperlink between the ache reliever and autism, which the businesses have strongly disputed and described as scientifically unproven.
However final week, RFK Jr. additionally softened his stance, acknowledging there’s inadequate knowledge to help the connection, however persevering with to warning towards Tylenol’s use throughout being pregnant.
Associated: Residence Depot sees shift in buyer conduct
